Back

The type I IFN-IL-27 axis promotes mRNA vaccine-induced CD8+ T cell responses

Phan, A. T.; Aunins, E.; Cruz-Morales, E.; Dwivedi, G.; Bunkofske, M.; Eberhard, J. N.; Aldridge, D. L.; Said, H.; Banda, O.; Tam, Y.; Christian, D. A.; Vonderheide, R. H.; Kedl, R. M.; Weissman, D.; Alameh, M.-G.; Hunter, C. A.

2025-01-21 immunology
10.1101/2025.01.16.633383 bioRxiv
Show abstract

The ability of lipid nanoparticle (LNP)-delivered mRNA vaccines to induce type I IFNs is critical to promote CD8+ T cell responses. The studies presented here indicate that immunization with nucleoside modified mRNA-LNP vaccines drives myeloid cell expression of the cytokine IL-27, which acts on antigen-specific CD8+ T cells to sustain T cell expansion. In vitro and in vivo studies revealed that type I IFN signaling is necessary for mRNA-LNP-induced IL-27 production, that immunization failed in IL-27 KO mice, and that immunization of IFNAR1-deficient mice with mRNA-LNP particles that also encode IL-27 mRNA restored antigen-specific CD8+ T cell responses. In addition, IL-27 mRNA-LNPs served as an adjuvant that improved cytolytic CD8+ T cell responses and the therapeutic efficacy of mRNA-LNPs to drive anti-pathogen and anti-tumor immunity. These studies highlight the central role of IL-27 in mRNA-LNP induced CD8+ T cell responses and the ability of this cytokine to augment the functionality of the CD8+ T cell response for prophylactic or therapeutic immunization.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.